KRP-114V phase III clinical trials - a double-blind comparative study over to verify the efficacy and safety of KRP-114V with an overactive bladder patients targeted

Trial Profile

KRP-114V phase III clinical trials - a double-blind comparative study over to verify the efficacy and safety of KRP-114V with an overactive bladder patients targeted

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Vibegron (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Sponsors Kyorin Pharmaceutical
  • Most Recent Events

    • 06 Jun 2017 According to the Roivant Sciences media release, the primary endpoint Efficacy (The average number of urgency per 1 day, etc.), Safety Timepoints Bladder diary, Adverse event and adverse drug reaction has been met.
    • 13 May 2016 Status changed from recruiting to active, no longer recruiting.
    • 25 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top